<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; MF Global Ltd</title>
	<atom:link href="http://www.stockbloghub.com/tag/mf-global-ltd/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(AA) Stock Market News for October 26, 2011 &#8211; Market News</title>
		<link>http://www.stockbloghub.com/2011/10/26/aa-stock-market-news-for-october-26-2011-market-news/85927</link>
		<comments>http://www.stockbloghub.com/2011/10/26/aa-stock-market-news-for-october-26-2011-market-news/85927#comments</comments>
		<pubDate>Wed, 26 Oct 2011 16:19:11 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Aluminum]]></category>
		<category><![CDATA[Basic Materials]]></category>
		<category><![CDATA[3M Company]]></category>
		<category><![CDATA[AA]]></category>
		<category><![CDATA[Alcoa Inc.]]></category>
		<category><![CDATA[Amazon.com Inc]]></category>
		<category><![CDATA[AMZN]]></category>
		<category><![CDATA[BAC]]></category>
		<category><![CDATA[Bank of America Corporation]]></category>
		<category><![CDATA[BP]]></category>
		<category><![CDATA[BP plc]]></category>
		<category><![CDATA[Cisco Systems]]></category>
		<category><![CDATA[CMI]]></category>
		<category><![CDATA[CSCO]]></category>
		<category><![CDATA[Cummins Inc.]]></category>
		<category><![CDATA[DD]]></category>
		<category><![CDATA[EI DuPont de Nemours & Company]]></category>
		<category><![CDATA[Hewlett-Packard Company]]></category>
		<category><![CDATA[HPQ]]></category>
		<category><![CDATA[INTC]]></category>
		<category><![CDATA[Intel Corporation]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[MF]]></category>
		<category><![CDATA[MF Global Ltd]]></category>
		<category><![CDATA[MMM]]></category>
		<category><![CDATA[Texas Instruments Inc.]]></category>
		<category><![CDATA[TXN]]></category>
		<category><![CDATA[United Parcel Service Inc.]]></category>
		<category><![CDATA[UPS]]></category>
		<category><![CDATA[Xerox Corporation]]></category>
		<category><![CDATA[XRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=85927</guid>
		<description><![CDATA[The benchmarks’ three-day rally hit a roadblock as the lack of conviction among investors about European leaders finding a solution to the region’s debt crisis on Wednesday’s summit and disappointing domestic corporate earnings weighed down the markets. Markets reversed their winning streak and posted heavy losses with the Dow Jones Industrial Average (DJIA) plummeting 205 points or 1.7% to settle at 11,708.44. The Standard &#38; Poor 500 (S&#38;P 500) declined 2.0% to finish at 1,229.23. The tech-laden Nasdaq Composite Index plunged 2.3% and closed at 2,638.42. Just a day after the fear-gauge CBOE Volatility Index (VIX) dropped below the key-level of 30, incremental anxiety among investors once again took it 10% higher to trade over 32. However, on a day of sharp declines, the markets continued the trend of low ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/10/26/aa-stock-market-news-for-october-26-2011-market-news/85927/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(INCY) Incyte Corporation Analyst Maintains Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/06/16/incy-incyte-corporation-analyst-maintains-neutral-on-shares/76486</link>
		<comments>http://www.stockbloghub.com/2011/06/16/incy-incyte-corporation-analyst-maintains-neutral-on-shares/76486#comments</comments>
		<pubDate>Thu, 16 Jun 2011 14:25:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[INCY]]></category>
		<category><![CDATA[Incyte Corporation]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MF]]></category>
		<category><![CDATA[MF Global Ltd]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76486</guid>
		<description><![CDATA[We are maintaining our Neutral recommendation on Incyte Corporation (INCY) with a target price of $18.00. Incyte is a Wilmington, Delaware-based drug discovery and development company with a focus on oral compounds to treat HIV, inflammation and cancer. The company&#8217;s lead compound is INCB18424, an oral janus-associated kinase (JAK) antagonist. Incyte is currently seeking US approval of INCB18424 for treating patients suffering from myelofibrosis (MF), a rare bone marrow disorder. Incyte submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for INCB424 earlier in the month. The company expects to launch INCB18424 for MF in the US later this year (assuming that the FDA reviews the application on a priority basis). We believe that if INCB 18424 is approved and subsequently marketed successfully for MF ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/16/incy-incyte-corporation-analyst-maintains-neutral-on-shares/76486/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVS) Novartis Posts Solid First Quarter Sales</title>
		<link>http://www.stockbloghub.com/2011/04/27/nvs-novartis-posts-solid-first-quarter-sales/71906</link>
		<comments>http://www.stockbloghub.com/2011/04/27/nvs-novartis-posts-solid-first-quarter-sales/71906#comments</comments>
		<pubDate>Wed, 27 Apr 2011 17:54:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[INCY]]></category>
		<category><![CDATA[Incyte Corporation]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MF]]></category>
		<category><![CDATA[MF Global Ltd]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71906</guid>
		<description><![CDATA[Novartis (NVS) reported earnings per share of $1.41 for the first quarter of 2011, below the year-earlier earnings of $1.45 per share but well ahead of the Zacks Consensus Estimate of $1.31. The drop from the base period resulted from financing costs for the Alcon acquisition completed in April this year. An increase in the number of shares outstanding, in the quarter, following dilution from the merger also affected earnings. Also marring earnings were robust profits booked in 2009 from windfall sales of H1N1 flu vaccines that were not to be repeated in the current quarter. First quarter revenues were up a solid 16% over the prior year to $14.0 billion. Total revenues also edged past the Zacks Consensus Estimate of $13.4 billion, driven by strong performance of newly launched ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/27/nvs-novartis-posts-solid-first-quarter-sales/71906/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GS) Company News for April 20, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/04/20/gs-company-news-for-april-20-2011-corporate-summary/71976</link>
		<comments>http://www.stockbloghub.com/2011/04/20/gs-company-news-for-april-20-2011-corporate-summary/71976#comments</comments>
		<pubDate>Wed, 20 Apr 2011 21:35:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diversified Investments]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[IBM]]></category>
		<category><![CDATA[International Business Machines]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[MF]]></category>
		<category><![CDATA[MF Global Ltd]]></category>
		<category><![CDATA[MICC]]></category>
		<category><![CDATA[Millicom International Cellular SA]]></category>
		<category><![CDATA[MOH]]></category>
		<category><![CDATA[Molina Healthcare Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71976</guid>
		<description><![CDATA[• Johnson &#38; Johnson (NYSE:JNJ) reported Q1 EPS of $1.35, ex-items, ahead of the Zacks Consensus Estimate of $1.25 per share. Revenues for the quarter rose 3.5% year-over-year to $16.2 billion, beating the Zacks Consensus Estimate of $15.768 billion • Analysts at JPMorgan Chase &#38; Co. (NYSE:JPM) initiated coverage on shares of MF Global Holdings Ltd (NYSE:MF) with an &#8220;Overweight” rating and a price target of $10.00  on the stock • Credit Suisse initiated coverage Nielsen Hldg NV (NYSE:NLSN) with an “Outperform” rating and with a target price $34.00 on the stock • Analysts at Citigroup initiated coverage on NetSpend Holdings Inc (NASDAQ:NTSP) with a “Buy” rating and a $13.00 target price on the stock • Stifel Nicolaus analysts initiated coverage on OCZ Technology Group Inc. (NASDAQ:OCZ) with a “Buy” rating and with a $13.00 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/20/gs-company-news-for-april-20-2011-corporate-summary/71976/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(INCY) Incyte Loss Smaller Than Forecast &#8211; Revenues Strong</title>
		<link>http://www.stockbloghub.com/2010/11/15/incy-incyte-loss-smaller-than-forecast-revenues-strong/59408</link>
		<comments>http://www.stockbloghub.com/2010/11/15/incy-incyte-loss-smaller-than-forecast-revenues-strong/59408#comments</comments>
		<pubDate>Mon, 15 Nov 2010 22:14:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[INCY]]></category>
		<category><![CDATA[Incyte Corporation]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MF]]></category>
		<category><![CDATA[MF Global Ltd]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[SPA]]></category>
		<category><![CDATA[Sparton Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=59408</guid>
		<description><![CDATA[Incyte Corporation (INCY) suffered a loss of 26 cents per share in the third quarter of 2010. Loss in the reported quarter was narrower than the Zacks Consensus Estimate of a loss of 33 cents and the year-ago loss (excluding special items) of 39 cents per share. The strong performance in the quarter was attributable to a surge in revenues. Total revenues in the reported quarter jumped to $16.9 million from $939,000 in the year-ago quarter. Revenues were boosted by the receipt of $16.7 million in milestone payments from partners Novartis (NVS) and Eli Lilly &#38; Co. (LLY).  Revenues were in line with the Zacks Consensus Estimate. Total cost and expenses in the reported quarter climbed 19.8% to $38.9 million. Both research and development (R&#38;D) expenses (up 15.4%) and selling, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/15/incy-incyte-loss-smaller-than-forecast-revenues-strong/59408/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SNY) Sanofi-Aventis Announces Agreement to Acquire TargaGen</title>
		<link>http://www.stockbloghub.com/2010/07/01/sny-sanofi-aventis-announces-agreement-to-acquire-targagen/42058</link>
		<comments>http://www.stockbloghub.com/2010/07/01/sny-sanofi-aventis-announces-agreement-to-acquire-targagen/42058#comments</comments>
		<pubDate>Thu, 01 Jul 2010 16:50:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[EXEL]]></category>
		<category><![CDATA[Exelixis Inc]]></category>
		<category><![CDATA[MF]]></category>
		<category><![CDATA[MF Global Ltd]]></category>
		<category><![CDATA[Micromet Inc]]></category>
		<category><![CDATA[MITI]]></category>
		<category><![CDATA[Regeneron Pharmaceuticals Inc]]></category>
		<category><![CDATA[REGN]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=42058</guid>
		<description><![CDATA[Sanofi-Aventis (SNY) continues to work on expanding its oncology portfolio with the company recently entering into an agreement to acquire TargaGen Inc. TargaGen, a privately-held US biopharmaceutical company, is focused on the development of candidates for the treatment of certain types of leukemia, lymphoma and other hematological malignancies and blood disorders. Deal Could be Worth $560M Per the terms of the agreement, TargaGen will receive $75 million once the transaction closes. Sanofi will make additional payments on the achievement of development milestones. Including the $75 million upfront payment, Sanofi could end up paying up to $560 million. The deal is scheduled to close in the third quarter of 2010. Deal to Expand Oncology Pipeline TargaGen’s lead pipeline candidate, TG101348, is an oral agent that is being developed for the treatment ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/01/sny-sanofi-aventis-announces-agreement-to-acquire-targagen/42058/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(INCY) Incyte Corporation Enters Into License Agreement With Novartis</title>
		<link>http://www.stockbloghub.com/2009/11/30/incy-incyte-corporation-enters-into-license-agreement-with-novartis/21550</link>
		<comments>http://www.stockbloghub.com/2009/11/30/incy-incyte-corporation-enters-into-license-agreement-with-novartis/21550#comments</comments>
		<pubDate>Tue, 01 Dec 2009 00:46:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[INCY]]></category>
		<category><![CDATA[Incyte Corporation]]></category>
		<category><![CDATA[MF]]></category>
		<category><![CDATA[MF Global Ltd]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=21550</guid>
		<description><![CDATA[Incyte Corporation (INCY) entered into a collaboration and license agreement with Novartis AG (NVS) regarding two of its pipeline candidates – INCB18424, an oral JAK1/JAK2 inhibitor and INCB28060, an oral cMET inhibitor. While the former is currently being studied in a phase III clinical trial for myelofibrosis (MF), the latter is yet to enter phase I trial as a potential treatment for multiple cancers. Along with MF, INCB18424 is in phase II trial for patients with advanced polycythemia vera (PV) and essential thrombocythemia (ET) As per the terms of the agreement, Incyte will retain exclusive rights for the development and potential commercialization of INCB18424 in the US whereas outside the US, Novartis will have responsibility for its future development and commercialization in all indications. In addition, Novartis will also be ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/30/incy-incyte-corporation-enters-into-license-agreement-with-novartis/21550/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

